Vaccine Research Center Senior Leadership

Deputy Directors





Julie E Ledgerwood, D.O.

Julie E. Ledgerwood, D.O.

Credit
NIAID

Julie E. Ledgerwood, D.O.

Credit:
NIAID

Julie E. Ledgerwood
Deputy Director
Chief Medical Officer

Julie E. Ledgerwood, D.O., is the Deputy Director and Chief Medical Officer at the Vaccine Research Center (VRC), NIAID, NIH. She is an international expert in the areas of pandemic response, vaccine research, and clinical trial design. She has conducted more than 70 investigational clinical trials studying vaccines and monoclonal antibodies (mAbs) targeting pathogens such as HIV, influenza, Ebola, malaria, Chikungunya, Zika, and SARS-CoV-2 in over 15 countries. In her years of clinical research, Dr. Ledgerwood has authored over 120 publications in peer-reviewed journals.

She has conducted clinical research with numerous academic and biotech/pharmaceutical industry clinical research teams and has led international vaccine research collaborations for multiple infectious disease targets. Regarding HIV prevention and treatment strategy assessment, Dr. Ledgerwood has skillfully led first in human evaluations of an extensive group of broadly neutralizing human monoclonal antibodies. She also led clinical evaluation of multiple candidate Ebola vaccines and of a potent Ebola mAb (mAb114) including an Expanded Access Protocol and randomized controlled trial for treating patients in the 2018-2020 DRC Ebola outbreaks. She was part of the initial isolation of this mAb from an Ebola virus survivor, thereby being involved in the full cycle of discovery to implementation of a successful public health intervention.

For her work, Dr. Ledgerwood has received numerous awards including elected membership to the American Society for Clinical Investigation, The Politico 50: Thinkers, Doers and Visionaries Transforming American Politics in 2015, and multiple NIAID and NIH Director's awards. She serves as a member of the Clinical Infectious Diseases faculty at the NIH and as adjunct faculty for the Walter Reed National Military Medical Center Department of Allergy and Immunology. She is a graduate of Oklahoma State University College of Osteopathic Medicine, completed her residency in internal medicine at Johns Hopkins Bayview Medical Center and a fellowship in allergy and immunology at the NIH. Dr. Ledgerwood is board-certified in allergy and immunology.

 





Richard Koup, M.D.

Richard A. Koup, M.D.

Credit
NIAID

Richard A. Koup, M.D.

Credit:
NIAID

Richard A. Koup, MD
Deputy Director
Chief, Immunology Laboratory

Dr. Koup received a B.S. in Biophysics and a M.S. in Biochemistry from the University of Connecticut and his M.D. from the Johns Hopkins University School of Medicine. Dr. Koup did his internship and residency in Internal Medicine at the Rhode Island Hospital and a fellowship in Infectious Diseases at the University of Massachusetts Medical School. Dr. Koup has held appointments at the Aaron Diamond AIDS Research Center, New York University Medical Center, and the Rockefeller University. From 1997 to 2001 he was the Jay P. Sanford Professor, and Chief of the Division of Infectious Diseases at the University of Texas Southwestern Medical Center in Dallas. In 2001 Dr. Koup moved to the NIH to join the Vaccine Research Center as a tenured Senior Investigator and Chief of the Immunology Laboratory. Since 20013 he has also served as Deputy Director of the Vaccine Research Center.

Dr. Koup studies the protective role of HIV-specific cellular immunity. His major discoveries include defining the temporal association between the first appearance of cytotoxic T cells and the decline in viremia during acute infection, delineating the role of the thymus in HIV pathogenesis, showing that HIV specific CD4+ T cells are preferentially infected and depleted by HIV, determining that the quality, not just the quantity, of the T cell response to HIV is crucial for maintaining control over HIV replication, and he has defined the critical role of follicular T helper cells in the development of broadly neutralizing antibodies against HIV.

Dr. Koup has trained over 35 pre- and post-doctoral students and co-authored over 300 papers on HIV and related topics. He serves on the editorial boards of several journals, and as a section editor for PLoS Pathogens. Dr. Koup is a fellow of the Infectious Diseases Society of America (IDSA) and has been elected to the American Society of Clinical Investigation (ASCI) and the Association of American Physicians (AAP).

Content last reviewed on